Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men
Emma Killick(Institute of Cancer Research), Hardev Pandha(Royal Surrey County Hospital), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Christina G. Selkirk(NorthShore University HealthSystem), Jimmy Lam(Flinders Medical Centre), Zsofia Kote‐Jarai(Institute of Cancer Research), Francesca Launchbury(University of Surrey), Susan M. Domchek(University City Science Center), Ignacio Blanco(Hospital Universitari Germans Trias i Pujol), Elena Castro(Research Institute Hospital 12 de Octubre), Richard Morgan(University of Surrey), Geoffrey J. Lindeman(The University of Melbourne), J. Zgajnar(Institute of Oncology Ljubljana), D. Gareth Evans(Manchester Academic Health Science Centre), Virginia Clowes(London North West Healthcare NHS Trust), Fiona Douglas(University of Southern California), Marion Harris(Peter MacCallum Cancer Centre), Judy Kirk(Westmead Hospital), Gillian Mitchell(Peter MacCallum Cancer Centre), Elizabeth Page(Institute of Cancer Research), Armen Aprikian, Kathy Tucker(Prince of Wales Hospital), Elizabeth Bancroft(Royal Marsden NHS Foundation Trust), Diana Eccles(Princess Anne Hospital), Nicholas Pachter(The University of Western Australia)
Cited by 35
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k